Non-Small Cell Lung Cancer (NSCLC) Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The non-small cell lung cancer (NSCLC) market size has grown rapidly in recent years. It will grow from $20.1 billion in 2024 to $22.35 billion in 2025 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to evolution of immunotherapy, genomic profiling and precision medicine, expansion of clinical trials, smoking cessation initiatives.

The non-small cell lung cancer (NSCLC) market size is expected to see rapid growth in the next few years. It will grow to $33.29 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to emerging combination therapies, integration of artificial intelligence (AI), expansion of personalized vaccines, global collaborations in research, patient-centric care. Major trends in the forecast period include integration of telemedicine in oncology, liquid biopsy technologies, advances in diagnostic technologies, adoption of minimally invasive surgical techniques, immune checkpoint inhibitors.

The rising rate of tobacco consumption is anticipated to drive the growth of the non-small cell lung cancer (NSCLC) market in the coming years. Tobacco consumption refers to individuals' use of tobacco products, commonly through smoking, chewing, or snuffing, which introduces nicotine and other chemicals into the body. Tobacco smoke contains numerous carcinogens that can damage DNA (deoxyribonucleic acid) in lung cells, leading to mutations and the uncontrolled growth of cancerous cells, including non-small cell lung cancer (NSCLC). For instance, according to the 2024 National Youth Tobacco Survey published by the U.S. Food and Drug Administration (USFDA), a U.S.-based federal agency, in October 2024, 1.1% of all students (around 2.25 million) reported current tobacco product use. This included 10.1% of high school students (approximately 1.58 million) and 5.4% of middle school students (about 640,000) who reported using tobacco; additionally, 2.8% of students (around 760,000) reported current use of any combustible tobacco product, while 3% (about 840,000) reported using multiple tobacco products. Consequently, the rising rate of tobacco consumption is fueling growth in the non-small cell lung cancer (NSCLC) market.

The anticipated growth of the non-small cell lung cancer (NSCLC) market is further driven by increasing air pollution. Harmful substances in the atmosphere, constituting air pollution, can adversely affect human health, increasing the risk of NSCLC through inflammation, DNA damage, and mutations in lung cells. The World Health Organization reported in June 2023 that air and household air pollution were linked to 7 million premature deaths annually. Additionally, approximately 2.4 billion people are exposed to dangerous levels of household air pollution. The World Bank further highlighted in September 2022 that health damage from air pollution amounts to $8.1 trillion annually, equivalent to 6.1% of global GDP. Thus, the growth of non-small cell lung cancer (NSCLC) is expected to be propelled by increasing air pollution.

Major companies in the non-small cell lung cancer (NSCLC) market are strategically developing multiple treatment options, including monotherapy treatments, to gain a competitive advantage. Monotherapy treatment, utilizing a single drug or therapy to address medical disorders, provides a focused approach. For instance, in June 2022, Novartis AG gained approval from the European Commission for Tabrecta (capmatinib) to treat adult patients with advanced NSCLC with METex14 skipping. This targeted therapeutic option addresses mutations causing MET exon 14 (METex14) skipping.

In August 2022, Bristol-Myers Squibb's acquisition of Turning Point Therapeutics for $4.1 billion enhances its ability to treat ROS1-positive NSCLC patients with the promising therapy, repotrectinib, developed by Turning Point Therapeutics. Repotrectinib holds the potential to improve outcomes for patients with ROS1-positive non-small-cell lung cancer. Turning Point Therapeutics specializes in developing precision medicines for NSCLC.

Major companies operating in the non-small cell lung cancer (NSCLC) market report are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., UCB S.A., Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Ferring B.V., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zydus Lifesciences Ltd., Lupin Limited, Torrent Pharmaceuticals Ltd., Almirall S.A., Clovis Oncology, Revolution Medicines.

North America was the largest region in the non-small cell lung cancer (NSCLC) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-small cell lung cancer (nsclc) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the non-small cell lung cancer (nsclc) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-small cell lung cancer (NSCLC) market includes revenues earned by entities by providing services such as targeted therapies, radiation therapies, imaging tests, biopsy, bronchoscopy, and lung function tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-small cell lung cancer (NSCLC) market also includes sales of chemotherapy drugs such as cisplatin, carboplatin, and pemetrexed epidermal growth factor receptor (EGFR) inhibitors such as erlotinib, afatinib, and gefitinib, as well as pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Non-small cell lung cancer (NSCLC) is a form of epithelial lung cancer that originates in the lung tissues, marked by the abnormal proliferation of cells. The primary causes of NSCLC include long-term smoking, genetic mutations, exposure to air pollution, and secondhand smoke.

The main subtypes of non-small cell lung cancer (NSCLC) are squamous cell carcinoma, large cell carcinoma, adenocarcinoma, and others. Squamous cell carcinoma originates from squamous epithelial cells and can manifest in various parts of the body. A variety of therapeutic approaches are employed for NSCLC, including radiotherapy, laser therapy, photodynamic therapy (PDT), and others. These therapeutic options are distributed through different channels, including hospital pharmacies, online pharmacies, and others.

The non-small cell lung cancer (NSCLC) market research report is one of a series of new reports that provides non-small cell lung cancer (NSCLC) market statistics, including non-small cell lung cancer (NSCLC) industry global market size, regional shares, competitors with a non-small cell lung cancer (NSCLC) market share, detailed non-small cell lung cancer (NSCLC) market segments, market trends and opportunities, and any further data you may need to thrive in the non-small cell lung cancer (NSCLC) industry. This non-small cell lung cancer (NSCLC) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.